An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas , Sept.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once again confirm the biological activity of simufilam. AUSTIN, Texas , Sept.